NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

Tandem Diabetes Care, Inc. (TNDM) Stock Analysis

Tandem Diabetes Care, Inc. (TNDM) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TNDM

$16.35

−$0.17 (−1.03%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TNDM with… →

TNDM Key Statistics

As of Oct 21, 2026
Trading
Open
$16.60
Previous Close
$16.52
Day's Range
16.13–16.95
52-Week Range
12.26–29.65
Volume
1.53M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.66
Valuation
Market Cap
$1.14B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
102.86
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.09
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.91
Financials (FY)
Revenue (FY)
$1.01B+7.93%
Net Income (FY)
−$204.71M
Profit marginThe share of revenue left as profit after all costs and taxes.
−6.08%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
69.58M
1-Year Return
+6.24%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
2.04M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TNDM closed at $16.35, +6.24% over 1 year.

Tandem Diabetes Care, Inc. (TNDM) has a market capitalization of $1.14B.

In fiscal 2025, TNDM reported revenue of $1.01B.

TNDM Stock Return by Calendar Year

Tandem Diabetes Care, Inc. (TNDM) 10-year return: what $10,000 became

1 year
$10,000 $10,624
+6.24%
5 years
$10,000 $1,283
−87.17%
10 years
$10,000 $2,440
−75.60%

If you had invested $10,000 in Tandem Diabetes Care, Inc. (TNDM) 10 years ago, at the close on October 21, 2016, it would have been worth $2,440 at the close on October 21, 2026: −75.60% in total, −13.16% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−25.61%
2025−38.98%
2024+21.77%
2023−34.19%
2022−70.14%
2021+57.32%
2020+60.51%
2019+56.99%
2018+1,508.90%
2017−89.02%
2016 (partial year)−68.52%

As of October 21, 2026.

TNDM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.01B−$204.71M−20.2%
2024$940.20M−$96.03M−10.2%
2023$747.72M−$222.61M−29.8%
2022$801.22M−$94.59M−11.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.01B$546.01M−$167.31M−$204.71M−20.2%
2024$940.20M$489.57M−$99.13M−$96.03M−10.2%
2023$747.72M$367.69M−$233.23M−$222.61M−29.8%
2022$801.22M$412.99M−$92.85M−$94.59M−11.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TNDM Valuation vs Medical Devices Median

Median of 145 stocks
MetricTNDMMedical Devices medianvs median
P/S ratio1.092.5357% below
Profit margin−6.08%−14.78%8.7 pts above

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Tandem Diabetes Care, Inc. (TNDM) is capitalised at $1.14B on the latest close. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 2,500.

TNDM last closed at $16.35 on October 21, 2026. That is −$0.17 (−1.03%) against the previous close. Over the past 52 weeks the price has ranged from $12.26 to $29.65. The latest close sits 33.36% above that 52-week low.

Financial Health

In fiscal 2025, Tandem Diabetes Care, Inc. reported revenue of $1.01B. That is +7.93% against the prior fiscal year, when revenue was $940.20M. The same year closed with a net loss of $204.71M. Profit margin runs at −6.08%. That is 8.7 percentage points above the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to −0.91.

Across the 4 fiscal years on file, revenue moves from $801.22M in 2022 to $1.01B in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 102.86. Measured against sales, the shares trade at 1.09 times revenue. On price-to-sales that is 56.82% below the Medical Devices median of 2.53. 145 Medical Devices companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.66. Daily returns over the trailing 10 years annualize to a volatility of 77.99%. The trailing one-year total return is +6.24%. Across 10 years the annualized return works out at −13.16%.

Growth & Income

The record shows no dividend for TNDM.

Across the complete calendar years on file, 2018 returned +1,508.90% and 2017 returned −89.02%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the total return is −25.61% year to date.

Peer Comparison

Tandem Diabetes Care, Inc. (TNDM) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tandem Diabetes Care, Inc. TNDM $1.14B —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. Tandem Diabetes Care, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Visit website →